632 related articles for article (PubMed ID: 24128373)
1. Short-term hemodynamic and neuroendocrine effects of pimobendan and benazapril in dogs with myxomatous mitral valve disease and congestive heart failure.
Häggström J; Lord PF; Höglund K; Ljungvall I; Jöns O; Kvart C; Hansson K
J Vet Intern Med; 2013; 27(6):1452-62. PubMed ID: 24128373
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Åblad B; Bussadori CM; Glaus T; Kovačević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir A; Lynne O'Sullivan M; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2013; 27(6):1441-51. PubMed ID: 24010489
[TBL] [Abstract][Full Text] [Related]
3. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
[TBL] [Abstract][Full Text] [Related]
4. Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
Boswood A; Gordon SG; Häggström J; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Schummer C; Watson P
J Vet Intern Med; 2018 Jan; 32(1):72-85. PubMed ID: 29214723
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
Boswood A; Häggström J; Gordon SG; Wess G; Stepien RL; Oyama MA; Keene BW; Bonagura J; MacDonald KA; Patteson M; Smith S; Fox PR; Sanderson K; Woolley R; Szatmári V; Menaut P; Church WM; O'Sullivan ML; Jaudon JP; Kresken JG; Rush J; Barrett KA; Rosenthal SL; Saunders AB; Ljungvall I; Deinert M; Bomassi E; Estrada AH; Fernandez Del Palacio MJ; Moise NS; Abbott JA; Fujii Y; Spier A; Luethy MW; Santilli RA; Uechi M; Tidholm A; Watson P
J Vet Intern Med; 2016 Nov; 30(6):1765-1779. PubMed ID: 27678080
[TBL] [Abstract][Full Text] [Related]
6. Effect of pimobendan on the incidence of arrhythmias in small breed dogs with myxomatous mitral valve degeneration.
Lake-Bakaar GA; Singh MK; Kass PH; Griffiths LG
J Vet Cardiol; 2015 Jun; 17(2):120-8. PubMed ID: 26007710
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
Vet Clin Pathol; 2013 Jun; 42(2):196-206. PubMed ID: 23614733
[TBL] [Abstract][Full Text] [Related]
8. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
Hezzell MJ; Block CL; Laughlin DS; Oyama MA
J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
[TBL] [Abstract][Full Text] [Related]
9. Effects of pimobendan on myocardial perfusion and pulmonary transit time in dogs with myxomatous mitral valve disease: a pilot study.
Apple SM; Menciotti G; Braz-Ruivo L; Crosara S; Häggström J; Borgarelli M
Aust Vet J; 2016 Sep; 94(9):324-8. PubMed ID: 27569835
[TBL] [Abstract][Full Text] [Related]
10. Effect of pimobendan on case fatality rate in Doberman Pinschers with congestive heart failure caused by dilated cardiomyopathy.
O'Grady MR; Minors SL; O'Sullivan ML; Horne R
J Vet Intern Med; 2008; 22(4):897-904. PubMed ID: 18537880
[TBL] [Abstract][Full Text] [Related]
11. Cardiorenal and endocrine effects of synthetic canine BNP1-32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease.
Yata M; Kooistra HS; Beijerink NJ
J Vet Intern Med; 2019 Mar; 33(2):462-470. PubMed ID: 30703246
[TBL] [Abstract][Full Text] [Related]
12. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs.
Lombard CW; Jöns O; Bussadori CM
J Am Anim Hosp Assoc; 2006; 42(4):249-61. PubMed ID: 16822763
[TBL] [Abstract][Full Text] [Related]
13. DELay of Appearance of sYmptoms of Canine Degenerative Mitral Valve Disease Treated with Spironolactone and Benazepril: the DELAY Study.
Borgarelli M; Ferasin L; Lamb K; Bussadori C; Chiavegato D; D'Agnolo G; Migliorini F; Poggi M; Santilli RA; Guillot E; Garelli-Paar C; Toschi Corneliani R; Farina F; Zani A; Dirven M; Smets P; Guglielmini C; Oliveira P; Di Marcello M; Porciello F; Crosara S; Ciaramella P; Piantedosi D; Smith S; Vannini S; Dall'Aglio E; Savarino P; Quintavalla C; Patteson M; Silva J; Locatelli C; Baron Toaldo M
J Vet Cardiol; 2020 Feb; 27():34-53. PubMed ID: 32032923
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
[TBL] [Abstract][Full Text] [Related]
15. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
[TBL] [Abstract][Full Text] [Related]
17. Heart rate, heart rate variability, and arrhythmias in dogs with myxomatous mitral valve disease.
Rasmussen CE; Falk T; Zois NE; Moesgaard SG; Häggström J; Pedersen HD; Ablad B; Nilsen HY; Olsen LH
J Vet Intern Med; 2012; 26(1):76-84. PubMed ID: 22151356
[TBL] [Abstract][Full Text] [Related]
18. Lowered N-terminal pro-B-type natriuretic peptide levels in response to treatment predict survival in dogs with symptomatic mitral valve disease.
Wolf J; Gerlach N; Weber K; Klima A; Wess G
J Vet Cardiol; 2012 Sep; 14(3):399-408. PubMed ID: 22858663
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
[TBL] [Abstract][Full Text] [Related]
20. Investigation of pimobendan versus benazepril in canine myxomatous valvular disease.
Boswood A; McEwan JD; French A; Little C; Swift S; Smith S; Patteson M
Vet Rec; 2003 Oct; 153(14):439-40. PubMed ID: 14582738
[No Abstract] [Full Text] [Related]
[Next] [New Search]